Does Kesimpta slow disability progression compared with Aubagio (teriflunomide)?
Note: The Prescribing Information calls the two identical phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, Study 1 and Study 2. The kesimptahcp.com clinical trial results page gives 0.65 points for a baseline EDSS of 5.5 or greater in a footnote to a post hoc subgroup analysis; the Prescribing Information, the FAQ page, and the Authorization and Appeals Kit give 0.5 points.